Anti Aging Research Peptides

44 research peptides demonstrate anti aging properties. This collection covers their mechanisms, evidence base, and research applications.

Ipamorelin stands out as a highly selective growth hormone secretagogue (GHS) that prompts the pituitary gland to release growth hormone (GH) in a pulsatile manner. This synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) is designed to minimize the influence on cortisol and prolactin levels, differentiating it from other GHSs. Studies indicate that Ipamorelin selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a), leading to increased intracellular cAMP levels and subsequent activation of protein kinase A, which facilitates GH secretion. Notably, its structural specificity allows it to engage only the GH-releasing pocket of the ghrelin receptor, avoiding the appetite stimulation and cortisol elevation associated with other peptides such as GHRP-6. The half-life of approximately 2 hours necessitates multiple daily administrations, yet its lack of receptor desensitization suggests a potential for prolonged use without diminishing effects.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has garnered attention for its ability to enhance GH and IGF-1 levels. Originally developed for HIV-associated lipodystrophy, it exists in two formulations: one with Drug Affinity Complex (DAC) for an extended half-life of 5.8-8.1 days, and another without DAC (Mod GRF 1-29) that mimics natural GH pulsatility with a half-life of about 30 minutes. Clinical trials, such as those conducted by Teichman et al. in 2006, demonstrated significant increases in GH and IGF-1 levels, reinforcing its potential therapeutic applications. The mechanism involves binding to GHRH receptors on pituitary somatotrophs, stimulating both GH gene transcription and release. While the DAC version maintains elevated GH levels, it may pose risks of receptor desensitization and insulin resistance. Conversely, Mod GRF 1-29 promotes a physiological release pattern that mitigates these risks, preserving the body's natural feedback mechanisms.

GHK-Cu, a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine), has been extensively studied for its role in skin and tissue repair. Discovered in 1973, its levels in human plasma decline with age, correlating with diminished regenerative capacity. The peptide binds copper ions, facilitating their delivery to cells while preventing oxidative damage. Research indicates that GHK-Cu stimulates collagen and elastin synthesis, modulates matrix metalloproteinases (MMPs), and promotes angiogenesis and fibroblast activation. Additionally, it activates TGF-beta signaling pathways, which are crucial for tissue remodeling and repair. Its antioxidant and anti-inflammatory properties further enhance its therapeutic potential. A broad safety profile has been established through decades of cosmetic use, yet the full extent of its biological effects, particularly in aging, warrants further investigation to fully elucidate its mechanisms and applications.

MOTS-c is a 16-amino-acid peptide derived from mitochondrial DNA that has emerged as a significant metabolic regulator. First identified in 2015, it has been shown to activate AMP-activated protein kinase (AMPK), a crucial player in cellular energy homeostasis. In preclinical mouse models, MOTS-c has demonstrated the ability to prevent diet-induced obesity and insulin resistance while enhancing exercise performance. Its mechanism involves retrograde signaling, where MOTS-c translocates from mitochondria to the nucleus, promoting the expression of genes associated with stress response and antioxidant defense. Furthermore, research suggests that MOTS-c may influence mTOR and inflammatory pathways, indicating its potential role in extending healthspan. While a modified analog has shown promising tolerability in human trials, further clinical studies are necessary to evaluate the effects of native MOTS-c in humans.

Sermorelin is a synthetic peptide that mimics the first 29 amino acids of growth hormone-releasing hormone (GHRH) and is notable for its ability to stimulate endogenous GH production while preserving the body's natural feedback mechanisms. The 1997 JCEM trial provided substantial evidence for its efficacy in improving IGF-1 levels, body composition, and overall well-being in adults over a 5-month period. Sermorelin operates by binding to GHRH receptors in the pituitary gland, promoting both GH gene transcription and its pulsatile release. This physiological approach contrasts with exogenous GH administration, reducing risks of insulin resistance and axis suppression. With a half-life of approximately 11-12 minutes, the regenerative processes initiated by Sermorelin can extend for weeks, making it a compelling candidate for research into age-related decline in GH levels and associated health outcomes.

Tesamorelin, an FDA-approved growth hormone secretagogue, has garnered attention for its ability to stimulate the endogenous production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Phase 3 clinical trials have demonstrated its efficacy in reducing visceral fat, with a notable safety profile observed over a 26-week treatment period. The peptide operates by binding to growth hormone-releasing factor (GRF) receptors in the anterior pituitary, mimicking the action of endogenous GRF. This results in increased GH synthesis and release, subsequently elevating IGF-1 and IGFBP-3 levels. The enhanced lipolysis and reduction of visceral adipose tissue are significant, particularly given the association between visceral fat and metabolic disorders. However, while Tesamorelin shows promise, its metabolic interactions, particularly regarding cytochrome P450 clearance, warrant further exploration to fully understand its implications in diverse patient populations.

Epithalon, a synthetic tetrapeptide developed by Russian gerontologist Vladimir Khavinson, has been primarily investigated for its potential to combat aging through telomere maintenance. Its mechanism involves the activation of telomerase, specifically the catalytic subunit TERT, which is crucial for extending telomeres at chromosome ends. While extensive research in Russian clinical settings has reported safety and potential efficacy, particularly in extending lifespan in animal models by up to 13.3%, Western clinical trials remain limited, raising questions about the generalizability of these findings. Additionally, Epithalon may enhance melatonin production, restore hormonal balance, and bolster antioxidant defenses, contributing to its anti-aging effects. However, its oral bioavailability is restricted due to digestive enzymes, and further studies are needed to elucidate its full therapeutic potential in diverse populations and to validate its effects in rigorous Western clinical trials.

SS-31, also known as Elamipretide, is a mitochondria-targeted tetrapeptide that has received FDA approval for specific mitochondrial diseases. Its unique mechanism involves selective accumulation in the inner mitochondrial membrane, where it binds to cardiolipin, stabilizing mitochondrial cristae and enhancing the integrity of the electron transport chain. By reducing the production of reactive oxygen species (ROS) at their source, SS-31 addresses mitochondrial dysfunction, which is often implicated in aging and various age-related diseases. Multiple clinical trials, including the TAZPOWER trial for Barth syndrome, have explored its efficacy and safety. While early results are promising, further investigation is necessary to understand the full spectrum of its effects on age-related mitochondrial dysfunction and to clarify its role in broader metabolic contexts.

FOXO4-DRI represents an innovative approach to targeting cellular senescence, a hallmark of aging characterized by the accumulation of dysfunctional cells that contribute to chronic inflammation and tissue degeneration. This D-retro-inverso peptide selectively induces apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53, a critical regulator of the cell cycle. By promoting p53 nuclear exclusion, FOXO4-DRI activates apoptotic pathways specifically within senescent cells, sparing healthy cells. This selectivity positions FOXO4-DRI as a promising candidate in the field of senolytics, with potential implications for age-related diseases. However, preclinical studies are still in their early stages, and further research is required to assess its long-term effects, optimal delivery methods, and overall safety in human populations.

Humanin is a mitochondria-derived peptide that has emerged as a significant player in neuroprotection and metabolic regulation. Initially identified for its neuroprotective properties against Alzheimer's disease-related toxicity, research has since unveiled its broader cytoprotective, anti-inflammatory, and anti-apoptotic effects. The peptide is encoded by the MT-RNR2 gene and its levels are known to decline with age, correlating with longevity in centenarian studies. Humanin exerts its effects through both intracellular and extracellular pathways, inhibiting pro-apoptotic proteins and activating survival signaling cascades. Notably, the S14G variant of Humanin exhibits dramatically increased potency, suggesting potential for therapeutic applications. While preclinical findings are compelling, further investigations are needed to establish its efficacy and safety in human subjects, particularly regarding its role in age-related metabolic dysfunctions.

NAD+ serves as a vital coenzyme in cellular metabolism, playing a critical role in redox reactions and as a substrate for various enzymes, including sirtuins and PARPs. Its levels decline significantly with age, approximately 50% between the ages of 40 and 60, which has sparked interest in NAD+ and its precursors like NMN and NR within the context of aging research. Although not a peptide, NAD+ is frequently discussed alongside peptides due to its potential implications in longevity. The coenzyme functions in several key processes: it acts as an electron carrier in metabolic pathways, supports DNA repair mechanisms, and influences gene expression through sirtuin activation. Age-related declines in NAD+ are associated with increased CD38 activity and decreased NAMPT function, contributing to metabolic dysregulation. While intravenous NAD+ administration shows high bioavailability, the short plasma half-life necessitates exploration of more sustainable delivery methods and formulations to optimize its potential benefits in aging.

Human growth hormone (hGH, somatotropin) is a 191-amino acid polypeptide synthesized by the anterior pituitary gland, recognized as a pivotal hormone in growth and metabolic regulation. It has been extensively studied, revealing its multifaceted role in various physiological processes.

Mechanism: hGH exerts its effects primarily through binding to the growth hormone receptor (GHR), which activates the JAK2-STAT5 signaling pathway and subsequently stimulates the hepatic production of insulin-like growth factor 1 (IGF-1). This pathway is crucial for mediating the growth-promoting effects attributed to hGH. Additionally, hGH influences metabolism by promoting lipolysis in adipose tissue and enhancing protein synthesis in muscle, while also exhibiting anti-insulin effects on glucose metabolism. Notably, hGH is secreted in a pulsatile manner, with peak levels occurring during slow-wave sleep. The endogenous half-life of hGH is approximately 20-30 minutes, whereas recombinant hGH, following subcutaneous administration, has an effective duration of 12-16 hours. Collectively, hGH impacts nearly all tissues in the body, underscoring its significance in growth and metabolism.

Collagen peptides, often referred to as hydrolyzed collagen, represent a diverse mixture of small peptides (typically 2-5 kDa) derived from the enzymatic hydrolysis of collagen obtained from various animal sources, including bovine, porcine, and marine origins. This category encompasses a range of bioactive peptide fragments rather than a singular peptide entity.

Mechanism: Upon oral ingestion, collagen peptides undergo partial digestion into smaller dipeptides and tripeptides, particularly those containing hydroxyproline, such as Pro-Hyp and Hyp-Gly. These fragments are absorbed into the bloodstream and subsequently accumulate in skin and cartilage, where they function as signaling molecules. Research suggests that they stimulate fibroblasts to enhance the production of type I collagen, elastin, and hyaluronic acid. Specifically, Pro-Hyp has been shown to promote dermal fibroblast proliferation and hyaluronic acid synthesis. In joint tissues, collagen-derived peptides may activate chondrocyte activity, leading to increased proteoglycan synthesis. Furthermore, these bioactive fragments exhibit antioxidant properties, contributing to their potential therapeutic effects. While multiple randomized controlled trials have reported generally positive outcomes regarding skin health, joint pain, and wound healing, the evidence quality remains moderate, with many studies being industry-funded and varying in formulation.

Matrixyl, a well-known cosmetic peptide, consists of the pentapeptide KTTKS, which is a fragment of type I procollagen, conjugated to a palmitic acid chain to enhance its penetration through the skin barrier. Developed by Sederma, Matrixyl was among the first cosmetic peptides to achieve widespread commercial adoption.

Mechanism: The KTTKS sequence is part of the C-terminal propeptide of type I procollagen. During collagen synthesis, this propeptide is cleaved, allowing the KTTKS fragment to signal fibroblasts to increase collagen production, thereby functioning as a positive feedback mechanism. The palmitoyl chain enhances trans-epidermal penetration, which is critical for its efficacy. In vitro studies have demonstrated that Matrixyl can upregulate the synthesis of collagen types I and III, as well as fibronectin in dermal fibroblasts. Additionally, it may stimulate the production of glycosaminoglycans, further contributing to skin hydration and elasticity. Although some clinical studies suggest modest anti-wrinkle effects, independent data remains limited, and the observed effect sizes are notably smaller compared to those associated with established treatments like retinoids.

Matrixyl 3000 is a trademarked cosmetic ingredient developed by Sederma, comprising a synergistic blend of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). This formulation aims to target skin aging through dual mechanisms, although clinical evidence largely stems from manufacturer-sponsored studies and a limited number of independent evaluations.

Mechanism: Palmitoyl tripeptide-1 (Pal-GHK) serves as a collagen-stimulating signal peptide, promoting fibroblast activity in collagen and glycosaminoglycan synthesis. Conversely, palmitoyl tetrapeptide-7 (Pal-GQPR) has been shown to reduce the secretion of interleukin-6 (IL-6), an inflammatory cytokine associated with skin aging processes, commonly referred to as inflammaging. The palmitoyl chains enhance skin penetration, facilitating the peptides' bioactivity. The combined action of these peptides aims to stimulate new collagen production while simultaneously mitigating the chronic low-grade inflammation that contributes to collagen degradation. Despite its popularity in cosmetic formulations, the clinical evidence supporting the efficacy of Matrixyl 3000 remains limited, necessitating further investigation to validate its anti-aging claims.